spacer
home > ebr > winter 2003 > cowpox to conjugates: trends in vaccines
PUBLICATIONS
European Biopharmaceutical Review

Cowpox to Conjugates: Trends in Vaccines

Vaccines are a group of products that include some of the oldest biological pharmaceutical entities. They are also an area where new techniques and manufacturing technologies are giving rise to significant growth. While eradication of some historic diseases has led to a lower need for prophylaxis, the resurgent threat of bioterrorism has given impetus to finding new and rapid methods for producing vaccines against a range of new and old threats, such as Anthrax.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ian Sellick, Director of Marketing at Pall Life Sciences

Ian Sellick is Marketing Director with Pall Life Sciences, where he is responsible for the spectrum of membrane-based technologies for separations and purification, and processing systems based on those technologies. Ian has 20 years' experience in the separations industries, the last eight with Pall Corporation. He holds an Honours degree in Zoology (with Cell Biology and Pharmacology) from the University of Bristol, and has post-graduate research experience in mucin biochemistry, growth dynamics and polymorphic isozymes of fish. Ian has published a large number of articles and papers, including papers on separations for food and dairy derived products, as well as the Institute of Brewing's book on beer filtration. He speaks regularly at conferences on separations for the biotechnology industry.

spacer
Ian Sellick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement